Asset Details
Do you wish to reserve the book?
Antiretroviral Concentrations in Breast-Feeding Infants of Women in Botswana Receiving Antiretroviral Treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antiretroviral Concentrations in Breast-Feeding Infants of Women in Botswana Receiving Antiretroviral Treatment
Do you wish to request the book?
Antiretroviral Concentrations in Breast-Feeding Infants of Women in Botswana Receiving Antiretroviral Treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Antiretroviral Concentrations in Breast-Feeding Infants of Women in Botswana Receiving Antiretroviral Treatment
2005
Overview
BackgroundThe magnitude of infant antiretroviral (ARV) exposure from breast milk is unknown MethodsWe measured concentrations of nevirapine, lamivudine, and zidovudine in serum and whole breast milk from human immunodeficiency virus type 1 (HIV-1)–infected women in Botswana receiving ARV treatment and serum from their uninfected, breast-feeding infants ResultsTwenty mother-infant pairs were enrolled. Maternal serum concentrations of nevirapine were high (median, 9534 ng/mL at a median of 4 h after nevirapine ingestion). Median breast-milk concentrations of nevirapine, lamivudine, and zidovudine were 0.67, 3.34, and 3.21 times, respectively, those in maternal serum. The median infant serum concentration of nevirapine was 971 ng/mL, at least 40 times the 50% inhibitory concentration and similar to peak concentrations after a single 2-mg/kg dose of nevirapine. The median infant serum concentration of lamivudine was 28 ng/mL, and the median infant serum concentration of zidovudine was 123 ng/mL, but infants were also receiving zidovudine prophylaxis ConclusionsHIV-1 inhibitory concentrations of nevirapine are achieved in breast-feeding infants of mothers receiving these ARVs, exposing infants to the potential for beneficial and adverse effects of nevirapine ingestion. Further study is needed to understand the impact of maternal ARV treatment on breast-feeding HIV-1 transmission, infant toxicity, and HIV-1 resistance mutations among infected infants
Publisher
The University of Chicago Press,University of Chicago Press,Oxford University Press
Subject
/ Anti-HIV Agents - pharmacokinetics
/ Anti-HIV Agents - therapeutic use
/ Botswana
/ Breasts
/ Dosage
/ Female
/ Highly active antiretroviral therapy
/ HIV 1
/ HIV Infections - drug therapy
/ HIV Infections - prevention & control
/ HIV Infections - transmission
/ HIV-1 - growth & development
/ HIV/AIDS
/ Humans
/ Infant
/ Infants
/ Infectious Disease Transmission, Vertical - prevention & control
/ Lamivudine - pharmacokinetics
/ Lamivudine - therapeutic use
/ Nevirapine - pharmacokinetics
/ Nevirapine - therapeutic use
/ Reverse Transcriptase Inhibitors - blood
/ Reverse Transcriptase Inhibitors - pharmacokinetics
/ Reverse Transcriptase Inhibitors - therapeutic use
/ Women
